<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Etanercept-associated myelitis</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName><forename type="first">Carsten</forename><surname>Finke</surname></persName>
							<email>carsten.finke@charite.de</email>
							<affiliation key="aff0">
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="institution">Charité -Universitätsmedizin Berlin</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="laboratory">Equal contribution</orgName>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Wolf</forename><surname>Schmidt</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="institution">Charité -Universitätsmedizin Berlin</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="laboratory">Equal contribution</orgName>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Eberhard</forename><surname>Siebert</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Department of Neuroradiology</orgName>
								<orgName type="institution">Charité -Universitätsmedizin Berlin</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Florian</forename><surname>Ostendorf</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="institution">Charité -Universitätsmedizin Berlin</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Etanercept-associated myelitis</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">830FD4E17719073E992E5E4361A0F933</idno>
					<idno type="DOI">10.1093/omcr/omv015</idno>
					<note type="submission">Received: December 8, 2014. Revised: February 4, 2015. Accepted: February 9, 2015</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:50+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract/>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Etanercept is an inhibitor of the pro-inflammatory and immunoregulatory cytokine tumor necrosis factor-α (TNFα).</s><s>It has been proved highly effective in the treatment of rheumatoid arthritis, psoriasis and ankylosing spondylitis, although several potentially severe side effects have been reported, including infections and allergic reactions.</s><s>Recently, attention has been drawn to an increased risk of demyelinating diseases in patients treated with TNFα inhibitors <ref type="bibr" target="#b0">[1]</ref>.</s><s>Here, we present a case of a patient who developed an acute demyelinating spinal cord lesion while being treated with etanercept.</s></p><p><s>We report on a 55-year-old woman with psoriatic arthritis without history of neurological symptoms.</s><s>She was on treatment with etanercept (50 mg weekly) for 6 months and did not take any other disease-modifying anti-rheumatic drugs when she presented with successively developing dysesthesia in the gluteal and genital region and in the lower extremities.</s><s>Examination showed gait ataxia, reduced joint position and vibratory sense at distal lower extremities and urinary dysfunction.</s><s>There were no clinical signs of infection and routine blood tests and CSF analysis were unremarkable.</s><s>MRI revealed a singular 8 mm hyperintense lesion in the dorsal thoracic spine and no further lesions in the brain or spinal cord were detected (Fig. <ref type="figure" target="#fig_0">1</ref>).</s><s>Etanercept was discontinued and treatment with IV methylprednisolone (1000 mg/day for 5 days) initiated, resulting in rapid alleviation of symptoms.</s><s>Skeletal scintigraphy showed no signs of active arthritis and the patient therefore was not re-started on a disease-modifying anti-rheumatic drug.</s><s>At follow-up 8 months later, remission persisted and the patient had no neurological deficits.</s><s>There were no clinical signs of psoriatic arthritis, although psoriatic skin changes recurred.</s></p><p><s>Our case highlights myelitis as a rare side-effect of etanercept that should prompt discontinuation of the drug and consideration of immunotherapy.</s><s>It is well known that TNFα inhibitors can increase the number of exacerbations and gadolinium-enhancing lesions in patients with multiple sclerosis (MS) and they are accordingly contraindicated in patients with a history of a demyelinating disorder <ref type="bibr" target="#b1">[2,</ref><ref type="bibr" target="#b2">3]</ref>.</s><s>More recently, peripheral and central demyelinating diseases have been reported in patients naïve of demyelinating events that were treated with TNFα inhibitors <ref type="bibr" target="#b0">[1,</ref><ref type="bibr" target="#b3">4]</ref>.</s><s>Observed disorders ranged from Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy (CIDP) to retrobulbar neuritis, demyelinating (MS-like) encephalitis and transverse myelitis.</s><s>Symptoms partially or fully resolved in the majority of patients after discontinuation of TNFα inhibitors and glucocorticoid treatment <ref type="bibr" target="#b0">[1,</ref><ref type="bibr" target="#b3">4]</ref>.</s><s>Arguments in favour of a true association between TNFα inhibition and occurrence of demyelination in our case include the temporal association between etanercept treatment and manifestation of symptoms and improvement of symptoms upon etanercept discontinuation.</s><s>A causal link is moreover supported by the report of similar disorders after exposure to TNFα inhibitors and positive re-challenge phenomena described in several cases <ref type="bibr" target="#b3">[4,</ref><ref type="bibr" target="#b4">5]</ref>.</s><s>Without rechallenge, our patient remained without neurological deficits after follow-up of 8 months.</s><s>Previous studies furthermore suggest that inhibition of TNFα induces complex alterations of immune homeostasis that are not restricted to suppression of pro-inflammatory actions (effective in the treatment of rheumatic diseases) but may also include promotion of autoimmune mechanisms <ref type="bibr" target="#b3">[4]</ref>.</s><s>The latter is in line with observations of stimulation of autoantibody production induced by treatment with TNFα inhibitors <ref type="bibr" target="#b5">[6]</ref>.</s><s>In summary, these observations strongly suggest a causal role of TNFα inhibition in the pathogenesis of myelitis in our patient, although there is no definite proof without a positive re-challenge phenomenon.</s></p><p><s>Taken together, our report demonstrates a rare but important side effect of etanercept treatment.</s><s>Clinicians thus need to consider demyelinating diseases as differential diagnosis in patients with TNFα inhibitor treatment that present with new neurological deficits.</s><s>In these patients, a discontinuation of etanercept treatment and IV glucocorticoid treatment is warranted.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Figure 1 :</head><label>1</label><figDesc><div><p><s>Figure 1: (a) Sagittal T 2 -weighted MRI shows a single posterior hyperintense demyelinating lesion of the cord at T5-6.</s><s>(b) Sagittal CE T 1 shows contrast enhancement of the lesion indicative of blood-spinal cord barrier disruption.</s><s>(c): On axial CE T1 the lesion is located dorsomedially and limited to the posterior columns.</s></p></div></figDesc></figure>
		</body>
		<back>
			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>CONFLICT OF INTEREST STATEMENT</head><p><s>The authors report no conflict of interest.</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Pattern of demyelination occurring during anti-TNF-α therapy: a French national survey</title>
		<author>
			<persName><forename type="first">R</forename><surname>Seror</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Richez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Sordet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Rist</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Gossec</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Direz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Rheumatology (Oxford)</title>
		<imprint>
			<biblScope unit="volume">52</biblScope>
			<biblScope unit="page" from="868" to="874" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">TNF neutralization in MS: results of a randomized, placebocontrolled multicenter study</title>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">53</biblScope>
			<biblScope unit="page" from="457" to="465" />
			<date type="published" when="1999">1999</date>
		</imprint>
		<respStmt>
			<orgName>The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group</orgName>
		</respStmt>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">W</forename><surname>Van Oosten</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Barkhof</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Truyen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">B</forename><surname>Boringa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">W</forename><surname>Bertelsmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Von</forename><surname>Blomberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Bme</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">47</biblScope>
			<biblScope unit="page" from="1531" to="1534" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Inflammatory neurological disease in patients treated with tumor necrosis factor alpha inhibitors</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Solomon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">I</forename><surname>Spain</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Kruer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Bourdette</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mult Scler</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="1472" to="1487" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Neurological adverse events associated with anti-tumor necrosis factor α treatment</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename><surname>Tristano</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neurol</title>
		<imprint>
			<biblScope unit="volume">257</biblScope>
			<biblScope unit="page" from="1421" to="1431" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Autoantibody production in anti-TNF-alphatreated patients</title>
		<author>
			<persName><forename type="first">C</forename><surname>Alessandri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Scrivo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">R</forename><surname>Spinelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Ceccarelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Magrini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Priori</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann NY Acad Sci</title>
		<imprint>
			<biblScope unit="volume">1110</biblScope>
			<biblScope unit="page" from="319" to="329" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
